NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006
Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010
Effectiveness of indacaterol and tiotropium in patients with severe dyspnoea Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Long-term safety of inhaled formoterol in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Efficacy of nebulized arformoterol, a long-acting β2 -adrenergic bronchodilator, in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Rational timing of combination therapy with tiotropium and formoterol in moderate-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 214s Year: 2006
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
The pharmacokinetics of inhaled NVA237 in COPD patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Comparison of efficacy and safety of Obucort Swinghaler with Pulmicot Turbuhaler in mild to moderate severe asthma patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Bronchodilator reversibility and short-term inhaled corticosteroid response in Japanese patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004